about
The crystal structure of recombinant rat pancreatic RNase AA single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loopsCanonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes?Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibodyDegenerate interfaces in antigen-antibody complexesThree camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topologyCrystal structure of the intrinsically flexible addiction antidote MazEA camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozymeGeneral strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffoldModulation of protein properties in living cells using nanobodiesA Nanobody Binding to Non-Amyloidogenic Regions of the Protein Human Lysozyme Enhances Partial Unfolding but Inhibits Amyloid Fibril FormationStructure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodiesHomo- and heteronuclear two-dimensional NMR studies of the globular domain of histone H1: full assignment, tertiary structure, and comparison with the globular domain of histone H5Crystal structure of a camel single-domain VH antibody fragment in complex with lysozymeNanobodies and recombinant binders in cell biologySpecific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapySelection and identification of single domain antibody fragments from camel heavy-chain antibodiesA versatile nanotrap for biochemical and functional studies with fluorescent fusion proteinsNaturally occurring antibodies devoid of light chainsTargeting and tracing antigens in live cells with fluorescent nanobodiesEngineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensingNanobodies: natural single-domain antibodiesSingle-domain antibodies as building blocks for novel therapeuticsAffinity is an important determinant of the anti-trypanosome activity of nanobodiesHomo- and heteronuclear two-dimensional NMR studies of the globular domain of histone H1: Sequential assignment and secondary structureNanobody-coupled microbubbles as novel molecular tracerNanobodies as novel agents for cancer therapy.Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens.Single domain camel antibodies: current status.Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm.An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology.Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen.The specific variable domain of camel heavy-chain antibodies is encoded in the germline.Efficient cancer therapy with a nanobody-based conjugate.A synthetic camel anti-lysozyme peptide antibody (peptibody) with flexible loop structure identified by high-resolution affinity mass spectrometry.Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains.Camelid nanobodies raised against an integral membrane enzyme, nitric oxide reductaseA novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire.A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomationTargeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody.
P50
Q27617726-03F6B7BD-BBC2-405F-8D0E-C1EAC0A5B2BEQ27617837-876C4232-CE06-408E-90D7-A1FFA32F7F55Q27625032-AE7CA4D4-D014-460E-B614-0400208EFB35Q27631669-232A5F8C-4096-45C4-8AB0-7EB3C0C91D5EQ27635520-A5E349BF-825A-49FA-A6C3-EE86785102CFQ27638877-13EF9153-3846-4E84-A823-00B178CD24CBQ27641242-A4826CF1-EF72-48F8-826F-6454831DE95BQ27641839-0A69B134-6EC9-4C93-B420-AB46E5822B02Q27652903-90A5B9A4-470F-41F5-8B1C-E9928B0813F6Q27658661-7DA42165-3EAB-44AE-A9E4-A79AA66D788FQ27679384-D2D5F418-493C-4857-974E-922CDB86914BQ27681380-F18757A5-EBE7-4425-B4DB-607A0C0FFD55Q27730200-38134F29-6BD8-4C73-8904-BDDC54C30828Q27733338-89B484F5-F4F9-40E0-811F-242B8A736B6DQ28081411-0DF56626-9E56-4B60-8502-0E4131246F01Q28238476-0485CC05-9A9E-4F8C-93DA-BFC664370D11Q28250517-FA725B1F-1E23-48A8-976F-036FD9E56FF8Q28254176-83639EC0-6B29-4883-9DEE-335491E9DDA3Q28269589-459D8C1C-71C7-46EF-B397-84A06C110FF7Q28270182-4C9B32F9-EEA4-429D-B958-89252B088EAEQ28284269-7433C68E-D9B8-4980-8A13-454F8B75D22DQ28287268-A27BC062-BCE5-488B-96FE-4D7783339192Q28290310-CF1AF5F8-EF80-45CD-BFB1-3BFEE52FF76FQ28485195-8785D7BF-C8B6-4647-B15D-DCEC4E9AB4FDQ29396509-07881BC5-0ABB-4AC7-8DBE-35183FF7D815Q30421973-D0A7DB70-D7EF-4637-9426-B46468CA0414Q30778309-E7E16780-B9B2-4E25-AADF-265193BC2632Q30837722-BF8DAFE7-371D-47BE-B34B-99997AF9B45CQ31005004-56CAD1A1-12A2-48CC-809E-4DB0C852E905Q31007389-B5C09AE7-70E4-4E18-8866-CFE55C6040EDQ31062653-CD360D6C-DED9-482C-B5E4-18B2BBF2CB5FQ31117894-36F75EEF-14E5-42DE-8B83-7C04ADE36435Q32121344-9301E52C-C6FE-4D5C-BF84-A0CE5F78B998Q33201668-EF903984-2094-4FCE-8888-850EE595BE1BQ33229623-2BB3DEBC-72B8-4E3C-8801-1097FE8B9DECQ33270541-E692F046-4C73-4DAA-8480-5A5E10DACFE1Q33412211-5EC4C854-357C-450E-87D1-8791873A972FQ33559542-F34B35B7-0548-4B2F-B4EE-FB88C90B465CQ33576215-3BD6C52D-8E63-4A1C-A524-E840E7F77F6CQ33686807-374F7443-9A70-4B76-80B9-187F5A8F4D03
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Serge Muyldermans
@ast
Serge Muyldermans
@de
Serge Muyldermans
@en
Serge Muyldermans
@es
Serge Muyldermans
@nl
Serge Muyldermans
@sl
type
label
Serge Muyldermans
@ast
Serge Muyldermans
@de
Serge Muyldermans
@en
Serge Muyldermans
@es
Serge Muyldermans
@nl
Serge Muyldermans
@sl
prefLabel
Serge Muyldermans
@ast
Serge Muyldermans
@de
Serge Muyldermans
@en
Serge Muyldermans
@es
Serge Muyldermans
@nl
Serge Muyldermans
@sl
P1006
P214
P244
P1006
P1053
C-6418-2016
P106
P21
P213
0000 0003 8355 7092
P214
P244
no2012131284
P31
P3829
P496
0000-0002-3678-3575
P7859
lccn-no2012131284